ArticleJournal of clinical laboratory analysis2026
Impact of COVID-19 Pandemic on Antibiotic Resistance Patterns of Common Bacterial Pathogens to Antibiotics in Northern Ghana.
Article in Journal of clinical laboratory analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dynamics of clinicalApplied and environmental microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBefore the COVID-19 pandemic, Northern Ghana reported high resistance to third-generation cephalosporins, but most bacteria remained susceptible to amikacin and meropenem. Increased antimicrobial use during the early COVID-19 pandemic likely heightened antimicrobial resistance. This study compared antimicrobial resistance before (October 2018-March 2020) and during (April 2020-December 2022) the COVID-19 pandemic in Ghana's Northern Region.
methodsA retrospective study was conducted at the Tamale Public Health Reference Laboratory. After the exclusion of incomplete records, 3677 culture cases were selected and analyzed. Antimicrobial susceptibility test results for all pathogenic bacteria were included.
resultsOf the 3677 cultures analysed, the majority were sputum samples (1792, 48.7%). From these, 1485 bacterial isolates covering 14 species underwent antimicrobial susceptibility testing. The predominant isolates were Klebsiella spp. (26%), Moraxella catarrhalis (20.7%), and Escherichia coli (18.4%). The majority of the participants were between the ages of (21-30) years. Antimicrobial resistance increased steadily above 50% from the third-quarter of 2021 to the second-quarter 2022. In a chi-square comparison, the susceptibility of bacteria to amoxiclav (p = 0.027), ceftazidime (p = 0.002), ciprofloxacin (p = 0.001), gentamycin (p = 0.035), and meropenem (p < 0.001) was significantly decreased during than before-COVID-19. The percentage increase in resistance observed was amoxiclav (8.8%), ceftazidime (7.9%), ciprofloxacin (9.2%), gentamicin (4.4%), and meropenem (16.7%).
conclusionOur findings reveal an increase in bacterial resistance to antibiotics during the COVID-19 pandemic, reinforcing the need for public health measures to optimize antibiotic use. We recommend further research to elucidate the molecular mechanisms underlying this bacterial resistance to antibiotics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.